| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825903 | Current Opinion in Pharmacology | 2016 | 6 Pages |
â¢Epicardial fat can be easily measured with imaging procedures.â¢Epicardial fat can be a therapeutic target of drugs targeting the adipose tissue.â¢Epicardial fat responds to TZDS, GLP-1RA, DPP4 inhibitors and statins.â¢Drug-induced browning of the epicardial fat is an interesting mechanism.â¢Pharmacogenetic targeting of epicardial fat transcriptome requires further studies.
Epicardial fat is the visceral fat depot of the heart. Given its rapid metabolism, organ fat specificity and simple objective measurability, epicardial fat can serve as target for pharmaceutical agents targeting the adipose tissue. Epicardial fat has shown to significantly respond to thiazolidinediones, glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors and statins. Epicardial fat may represent a measurable risk factor and modifiable therapeutic target. Targeted pharmaceutical interventions may allow the epicardial fat to resume its physiological role. A drug-induced browning effect on epicardial fat suggests the development of pharmacological strategies to increase energy consumption. The potential of modulating the epicardial fat transcriptome with targeted pharmacological agents can open new avenues in the pharmacotherapy of cardio-metabolic diseases.
